Skip to main content

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

The Original Article was published on 07 August 2021

Correction to: BMC Cancer 21, 904 (2021)

https://doi.org/10.1186/s12885-021-08630-w

Following publication of the original article [1], it was noticed that uncorrected page proofs were mistakenly published. The publishers apologise for this error. The original article [1] has been corrected.

Below is a table of corrections which have been implemented in the original article.

Section Originally published text Corrected text
Article note Rajesh Kaldate7 & Evelyn Wang7 Rajesh Kaldate7† & Evelyn Wang7†
Affiliation at the time of the study.
Abstract Trial registration: ClinicalTrials.gov NCT01865747 (registered on 05/31/2013). Trial registration: ClinicalTrials.gov NCT01865747 (registered on 05/31/2013). https://clinicaltrials.gov/ct2/show/NCT01865747
Table 1 note Plasma biomarker baseline and fold change data were available for 316 and 304 patients in the cabozantinib arm and 305 and 280 patients in the everolimus
arm, respectively, with the exception of for IL-8 in the everolimus arm, for which 304 and 279 patients had available data, respectively
Plasma biomarker baseline and fold change data were available for 316 and 304 patients in the cabozantinib arm and 305 and 280 patients in the everolimus arm, respectively, with the exception of IL-8 in the everolimus arm, for which 304 and 279 patients had available data, respectively
Figure 1 Footnote is missing High levels and low levels are defined by ≥median and < median, respectively.
NR, not reached.
Row 2 1.32 (0.95–1.83) 1.32 (0.95, 1.83)
Row 6 ΔIL8 ΔIL-8
Table 6
Row 11
IL8 IL-8
Table 6
Row 12
0.97 (0.87–1.07) 0.97 (0.87, 1.07)
Table 6
Row 16
ΔIL8 ΔIL-8
Table 6
Row 18
IL8 IL-8
Table 6
Row 21
IL8 / 1.35 (0.95–1.9) IL-8 / 1.35 (0.95, 1.9)
Table 6 note Biomarkers were included in the multivariable analysis if p < 0.10 in the univariate analyses. Hazard ratios are for high versus low biomarker levels. Δ Indicates the covariate is change in the biomarker at week 4; all other covariates are baseline biomarkers dichotomized at the median * p < 0.05 for the analysis Biomarkers were included in the multivariable analysis if p < 0.10 in the univariate analyses. Hazard ratios are for high versus low biomarker levels.
Δ indicates the covariate is change in the biomarker at week 4; all other covariates are baseline biomarkers dichotomized at the median * p < 0.05 for the analysis
Competing interests Dr. Powles has received honoraria from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has a consulting or advisory role with Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has received research funding from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and has received travel/accommodation/other expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Dr. Powles has received honoraria from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has a consulting or advisory role with Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has received research funding from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and has received travel/accommodation/other expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche.
Competing interests Dr. Wang is employed by Exelixis; and has stock/ownership interests with Exelixis. Dr. Wang is a former employee of Exelixis; has stock/ownership interests with Exelixis.
Additional file 1 ‘Track changed’ version was published Clean version is published this correction article and the original article has been udpated

Reference

  1. 1.

    Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, et al. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021;21(1):904. https://doi.org/10.1186/s12885-021-08630-w.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Thomas Powles.

Additional information

†Rajesh Kaldate and Evelyn Wang's affiliation at the time of the study.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Powles, T., Choueiri, T.K., Motzer, R.J. et al. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer 21, 1023 (2021). https://doi.org/10.1186/s12885-021-08693-9

Download citation